Romania Cancer Immunotherapy Market Analysis

Romania Cancer Immunotherapy Market Executive Analysis

Romania's cancer immunotherapy market is expected to witness growth from $326 Mn in 2022 to $575 Mn in 2030 with a CAGR of 7.3% for the forecasted year 2022-30. A total of $25 Bn, or 7.22% of GDP, is available for investment in various sectors. To improve healthcare, Romania is investing in three new regional hospitals that offer cutting-edge, centralized medical services. Overall, equipment quality and accessibility to new technologies are lower than in developed European nations, and modern services are more likely to be found in densely populated urban regions. This reduces the effectiveness and quality of healthcare while raising expenditures for both the healthcare system and its clients. The European Investment Bank's Project Advisory Support Service Agreement (PASSA) team is collaborating closely with the Romanian Ministry of Health to build three new regional hospitals and modify the existing healthcare system to strengthen the nation's healthcare system, upgrade hospital infrastructure, and provide quality services to its users.

According to information provided by the Federation of Cancer Patients Associations (FABC), cancer claims the lives of 140 Romanians every day and is often discovered too late. The main reason for the disease's late discovery is a lack of education and screening initiatives. The most prevalent type of cancer in both men and women is pulmonary cancer. Breast cancer, prostate cancer, bladder cancer, and gastric cancer come after it. Men are more likely to develop lung cancer than prostate, urinary bladder, stomach, or liver cancers. Breast cancer is the most prevalent cancer among women, followed by ovarian, cervical, lung, and endometrial cancers.

Cancer immunotherapy uses therapeutic approaches to influence the immune system by the administration of immunological agents like cytokines, vaccines, cell treatments, and transfection agents. The most promising advancement in cancer treatment since the creation of the first chemotherapies in the late 1940s is cancer immunotherapy, which involves medications that strengthen the immune system's natural ability to combat cancer. Immune checkpoint inhibitors, which target molecules that act as controls in the regulation of immune responses and either block inhibitory molecules or activate stimulatory molecules and enhance pre-existing anti-cancer immune responses, represent a promising area of clinical research in bladder cancer. There are ongoing recruitment efforts for trials utilizing Nivolumab, Ipilimumab, and Pertuzumab for metastatic bladder cancer.

Market Dynamics

Market Growth Drivers

Romania's rising cancer prevalence is predicted to increase demand for cancer immunotherapy treatments. The World Cancer Research Fund estimates that Romania will have about 75,000 new cases of cancer in 2020. Investments in cancer immunotherapy research and development are being made by the Romanian government and private investors. This investment is anticipated to result in the creation of novel and cutting-edge cancer immunotherapy therapies, which will promote the Romania cancer immunotherapy market's expansion. Technology developments, such as the creation of tailored cancer immunotherapy treatments, are anticipated to fuel market expansion. Treatments that are personalized to a patient's unique needs might improve their effectiveness and lessen their side effects.

Market Restraints

The lack of a developed healthcare system in Romania may prevent certain patients from receiving cancer immunotherapy therapies. This might lower the overall demand in Romania for cancer immunotherapy treatments. The cost of cancer immunotherapy treatments can be costly, and this may make them less accessible for some patients. This might lower the overall demand in Romania for cancer immunotherapy treatments. The Romanian healthcare system covers cancer therapies, although there may be restrictions on cancer immunotherapy payments. Patients may find it challenging to obtain these treatments as a result, which may restrict the Romania cancer immunotherapy market expansion.

Competitive Landscape

Key Players

• Terapia (ROU)
• Antibiotice (ROU)
• Biofarm (ROU)
• Worwag Pharma (ROU)
• Sunwave Pharma (ROU)
• AstraZeneca
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Pfizer
• Eli Lily
• Novartis
• Johnson & Johnson
• Merck

Healthcare Policies and Regulatory Landscape

The National Health Insurance Fund (CNAS) and the Ministry of Health are principally in charge of regulating cancer health insurance and reimbursement policies in Romania. Cancer patients in Romania have access to a variety of cancer therapies, including surgery, radiotherapy, chemotherapy, and targeted therapy. These treatments are all covered by the National Health Insurance Fund (CNAS). Nevertheless, depending on the cancer's stage, type, and patient's general condition, access to some treatments may be restricted. The National Catalogue of Reimbursed Products, which offers a list of medications and medical procedures that are covered by the public health insurance system, is used by the CNAS to reimburse for cancer treatments. The Ministry of Health, in addition to the CNAS, is involved in regulating cancer treatment policy in Romania. Setting norms and criteria for cancer therapy as well as managing the accreditation of cancer treatment facilities fall under the purview of the Ministry of Health. A network of oncology clinics and hospitals in Romania provides access to support services for cancer patients as well. For patients with advanced cancer, these clinics offer a variety of services such as psychological support, pain management, and palliative care.